Plasma cell-free tumor DNA, PIK3CA and TP53 mutations predicted inferior endocrine-based treatment outcome in endocrine receptor-positive metastatic breast cancer

[1]  A. Aravanis,et al.  Clinical correlates of circulating cell-free DNA tumor fraction , 2021, PloS one.

[2]  S. Jeffrey,et al.  Liquid biopsy enters the clinic — implementation issues and future challenges , 2021, Nature Reviews Clinical Oncology.

[3]  K. Pantel,et al.  Clinical relevance of blood-based ctDNA analysis: mutation detection and beyond , 2020, British Journal of Cancer.

[4]  F. Bertucci,et al.  Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  Yusuke Nakamura,et al.  Clinical significance of gene mutation in ctDNA analysis for hormone receptor-positive metastatic breast cancer , 2020, Breast Cancer Research and Treatment.

[6]  R. Hastings,et al.  Plasma cell-free DNA (cfDNA) as a predictive and prognostic marker in patients with metastatic breast cancer , 2019, Breast Cancer Research.

[7]  G. Romieu,et al.  PIK3CA mutations early persistence in cell-free tumor DNA as a negative prognostic factor in metastatic breast cancer patients treated with hormonal therapy , 2019, Breast Cancer Research and Treatment.

[8]  R. Kimmig,et al.  Targeted deep sequencing revealed variants in cell-free DNA of hormone receptor-positive metastatic breast cancer patients , 2019, Cellular and Molecular Life Sciences.

[9]  E. Winer,et al.  Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  Sam Angiuoli,et al.  Direct detection of early-stage cancers using circulating tumor DNA , 2017, Science Translational Medicine.

[11]  G. Hortobagyi,et al.  Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR+, HER2− advanced breast cancer: results from BOLERO-2 , 2017, British Journal of Cancer.

[12]  F. Diehl,et al.  Performance of Streck cfDNA Blood Collection Tubes for Liquid Biopsy Testing , 2016, PloS one.

[13]  Chiun-Sheng Huang,et al.  TP53 Mutational Analysis Enhances the Prognostic Accuracy of IHC4 and PAM50 Assays , 2015, Scientific Reports.

[14]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.